Latest Conference Articles

Diet, alcohol, and physical activity offer actionable targets for clinicians managing MASLD, according to Zobair M. Younossi, MD.

Phase 2 data show promising antiviral activity with tobevibart plus elebsiran in hepatitis D, supporting further evaluation in the phase 3 ECLIPSE program.

The shift toward fibrosis end points and noninvasive biomarkers in MASH trials may ease enrollment, improve assessment, and reduce biopsy use, Zobair M. Younossi, MD, said.

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

Moving to a subQ formulation makes sense, if you want to be 100% convenient for patients and the centers that treat them, explains Xavier Leleu, MD, PhD.

This research reinforces that fixed-duration, chemotherapy-free regimens can offer both a tolerability and a patient-experience advantage over CIT.

This analysis, presented by Rahul Banerjee, MD, FACP, at EHA 2026, builds on data that supported the FDA’s March 2026 approval of teclistamab.

INCA033989 showed responses across type 1 and type 2 mutant calreticulin-positive myelofibrosis, with phase 3 studies underway.

INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting disease-modifying potential.

Two studies identify molecular targets that could help preserve insulin-producing cell function.

As presented at EHA 2026, AGAVE-201 showed no significant bone health safety signals with axatilimab in chronic graft-versus-host disease (cGVHD).

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

emtelligent turns unstructured data into coded clinical insights, powering payer and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

ViroMissile shares phase 1 IDOV-Safe oncolytic virus results, showing IV activity in pMMR/MSS metastatic colorectal cancer and fueling US phase 2 plans.

SYNC-T from Syncromune delivers a 4-part localized immunotherapy regimen for metastatic prostate cancer, showing high response rates with low toxicity.

Kazia Therapeutics advances paxalisib, a dual PI3K/mTOR inhibitor, into triple-negative breast cancer, boosting immunotherapy responses with early promising data.

New research reveals complex treatment costs from MM strain patients and caregivers during active therapy, while pain goes undertreated at end of life.

Nipocalimab improved fatigue by week 2 in patients, supporting its potential as a fast-acting, patient-centered therapy, says Irina Murakhovskaya, MD.

Since sickle cell disease trial criteria exclude most patients, Julie Kanter, MD, advocated for broader end points and real-world monitoring to improve inclusion.

Selinexor plus ruxolitinib showed greater spleen reductions and an early survival signal in JAK-naive myelofibrosis, Claire Harrison, MD, explained.

Independent investigations found that venetoclax-based combination regimens achieved high response and strong MRD negativity in newly diagnosed leukemias.

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring adjuvant immunotherapy for patients with negative results for disease following surgery.

The 2026 conference, held in Baltimore, Maryland, offered expert insight into the past and future of sleep medicine.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

Flatiron Telescope uses AI and transparent SQL to turn real-world evidence into quick turnaround oncology research and FDA-ready analytics.

Armored DLL3 CAR T-cell therapy from Legend Biotech/Novartis shows early responses in small cell lung cancer and neuroendocrine tumors, according to presentation at ASCO.